Assuntos
Meios de Contraste , Sistemas de Liberação de Medicamentos , Fluorocarbonos , Ultrassonografia , Animais , Meios de Contraste/administração & dosagem , Dexametasona/administração & dosagem , Fluorocarbonos/administração & dosagem , Camundongos , Camundongos Endogâmicos BALB C , Compostos Orgânicos , Pró-Fármacos/administração & dosagemAssuntos
Meios de Contraste , Bicamadas Lipídicas , Ultrassonografia , Animais , Meios de Contraste/toxicidade , Ecocardiografia , Gases , Bicamadas Lipídicas/toxicidade , Lipossomos , Camundongos , Camundongos Endogâmicos BALB C , Infarto do Miocárdio/diagnóstico por imagem , Tamanho da Partícula , Coelhos , SuínosRESUMO
Liposomes with a mean diameter of 1-2 microns were made to entrap nitrogen gas and tested as an ultrasound (US) contrast agent. The gas-filled liposomes, or Aerosomes (ImaRx Pharmaceutical, Tucson) were tested in vitro for size, stability, reflectivity, and acoustic characterization, and were tested in vivo for acute toxicity in mice and for cardiac imaging in rabbits after intravenous injection. Aerosomes have much greater reflectivity and higher attenuation than do standard liposomes and retain their acoustic properties after storage in aqueous media for several months. The interpolated median lethal dose of Aerosomes is approximately 2.5 mmol of lipid per kilogram, and the imaging dose is under 5 mumol of lipid per kilogram, yielding a potential therapeutic index of over 500 to 1. Postcontrast US images showed sustained enhancement of all four cardiac chambers as well as enhancement in the aorta, vena cava, and hepatic veins. Aerosomes hold promise as a contrast agent for cardiac and blood-pool imaging. Further work is in progress to characterize and develop this novel US contrast agent.